|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, FN1, TIMP1, MMP2, and SPARC are correlated with SERPINE1 and may serve as therapeutic targets in reversing EMT in GC.
|
31218131 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further analysis showed high expression of CXCL8, COL3A1, CXCL1, MMP3 and SERPINE1, were significantly associated with late stage of GC.
|
31638362 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strains of <i>Helicobacter pylori</i> that cause ulcer or gastric cancer typically express a type IV secretion system (T4SS) encoded by the <i>cag</i> pathogenicity island (<i>cag</i>PAI).
|
29764950 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The investigations of SERPINE1 and SPARC may promote their predictive and prognostic value in GC.
|
30410354 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus far, many virulence factors of H. pylori, such as Cag PAI, VacA, OMPs and DupA, have been reported to be involved in the development of gastric cancer.
|
26346770 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-30b may function as a novel tumor suppressor gene in gastric cancer by targeting PAI-1 and regulating the apoptosis of cancer cells. miR-30b could serve as a potential biomarker and therapeutic target against gastric cancer.
|
25170877 |
2014 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.
|
22098548 |
2012 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Microsatellite instability and loss of heterozygosity of the PAI-1 gene apparently regulates the development of gastric cancer through different pathways.
|
22653645 |
2012 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variants of the genes IL-10, IL-17, MUC1, MUC6, DNMT3B, SMAD4, and SERPINE1 have been reported to modify the risk of developing GC.
|
21896084 |
2011 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Five tag single nucleotide polymorphisms (SNPs) and 1 insertion polymorphism within SERPINE1 were genotyped in 1101 unrelated Korean individuals (a case group of 612 patients with gastric cancer and a control group of 489 healthy individuals).
|
20549826 |
2010 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
H. pylori isolates with intact cag-PAI were associated with gastric carcinoma (GC; n=9 [60%]) and gastric ulcer (GU; n=5 [45%]) compared to non-ulcer dyspepsia (NUD; n=14 [18%]) (P=0.001 and P=0.049, respectively).
|
19839224 |
2009 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggested that PAI-1 might serve as a new and promising parameter for the prediction of prognosis in gastric cancer.
|
16630137 |
2006 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cag-PAI is a strong virulent marker in the disease pathogenesis as it is shown that a large number of those infected with strain with complete cag-PAI had one or the other of the irreversible gastric pathologies and interestingly 18.5% of them developed gastric carcinoma.
|
16425389 |
2005 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
c-erbB-2 is confirmed as a new independent, functional prognostic parameter for overall survival in gastric cancer, even when a panel of invasion-related factors, including the strong prognostic parameter PAI-1, are considered.
|
10829039 |
2000 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To clarify the relationship between these two factors and gastric cancer invasiveness, we evaluated the expression of uPAR and PAI-1 in 91 cases of gastric cancer by immunohistochemistry and in situ hybridization.
|
9794194 |
1998 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAI-1 expression was observed in 62 (50%) of 125 gastric cancer as a fine, diffuse and granular pattern in the cytoplasm.
|
8624578 |
1996 |